目的 觀察復(fù)方丹參片及其拆方對(duì)冠心病心肌缺血大鼠模型的影響。方法 SD大鼠隨機(jī)分為假手術(shù)組，模型組，復(fù)方丹參片高、低劑量（0.6、0.3 g/kg）組，單硝酸異山梨酯片（陽(yáng)性藥，6.9 mg/kg）組，丹參提取物（0.3 g/kg）組，三七粉（0.3 g/kg）組，ig給藥，每日1次，預(yù)防給藥7 d，末次給藥1 h后結(jié)扎冠脈左前降支制備心肌缺血大鼠模型。檢測(cè)大鼠結(jié)扎前及結(jié)扎后Ⅱ?qū)碾妶D，觀察ST段變化值；最后一次心電圖檢測(cè)后腹主動(dòng)脈取血，ELISA法檢測(cè)血清肌酸激酶同工酶（CK-MB）、乳酸脫氫酶（LDH）、天門冬氨酸轉(zhuǎn)氨酶（AST）、一氧化氮（NO）、一氧化氮合成酶（eNOS）、內(nèi)皮素（ET）、血栓素（TXB2）、前列環(huán)素（6-keto-F1α）水平；取心臟，TTC染色檢測(cè)心肌缺血率。結(jié)果 與對(duì)照組比較，模型組心電圖ST段顯著抬高，心肌缺血明顯，血清心肌酶AST、LDH、CK-MB水平均顯著升高，TXB2水平顯著升高，6-keto-F1α水平顯著降低，NO、eNOS水平顯著降低，ET水平顯著升高（P<0.01、0.001）。與模型組比較，復(fù)方丹參片高、低劑量組心電圖ST段抬高顯著改善，心肌缺血率顯著降低，血清各生化指標(biāo)均顯著改善（P<0.05、0.01）；丹參提取物組心電圖ST段抬高，心肌缺血率，血清CK-MB、LDH、eNOS、ET、TXB2、6-keto-F1α水平均顯著改善（P<0.05），AST和NO水平差異無(wú)統(tǒng)計(jì)學(xué)意義；三七粉組心電圖ST段、血清CK-MB、ET、TXB2、6-keto-F1α顯著改善（P<0.05），心肌缺血率和AST、LDH、NO、eNOS水平差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 在改善冠心病大鼠心肌缺血方面，復(fù)方丹參片效果較單味藥好，丹參提取物效果較三七粉效果較好。

Objective To observe the effect of Compound Danshen Tablet and its disassembled formula on the rat model of myocardial ischemia of coronary heart disease. Methods SD rats were randomly divided into sham operation group, model group, high and low dose groups (0.6 g/kg, 0.3 g/kg) of Compound Danshen Tablet, positive drug group (isosorbide mononitrate 6.9 mg/ kg), Danshen Extract group (0.3 g/kg), Sanqi powder group (0.3 g/kg). Rats were continuous administrated by gavage once a day for 7 days. One hour after the last administration, the left anterior descending of coronary artery (LAD) of rat was ligated to prepare the model of myocardial ischemia. Before and after ligation, the ECG of rat was respectively measured at 5, 15, 30, 45, 60, 90, 120, 180 min and 24 h, and the change of ST segment was determined. After the last ECG, the blood was taken from abdominal aorta, then detecting the level of CK-MB, LDH, AST, NO and eNOS, ET, TXB2, and 6-keto-F1α by ELISA assay. And the heart was taken to detect the infarct area. Results Compared with control group, the ST segment of ECG in the model group was significantly elevated, myocardial ischemia was significant, serum myocardial enzyme AST, LDH, CK-MB levels were significantly increased, TXB2 level was significantly increased, 6-keto-f1 α level was significantly reduced, NO, eNOS level was significantly reduced, ET level was significantly increased (P<0.01, 0.001). Compared with the model group, the ECG on the high and low dose group of Compound Danshen Tablet was significantly improved, as well as the index of vasomotor factor. Furthermore, Compound Danshen Tablet could decrease the serum myocardial enzyme and the antithrombotic index, the difference was statistically significant (P<0.01). ST segment of ECG, CK-MB, LDH, eNOS, ET, TXB2, 6-keto-F1α in Danshen Extract group were significantly improved (P<0.05), while AST and NO had no significantly difference. The other formula, Sanqi could significantly improve the ST segment of ECG, CK-MB, ET, TXB2 and 6-keto-F1α (P<0.05), but AST, LDH, NO and eNOS were not significantly changed. Conclusion According to experimental results, Compound Danshen Tablet showed the best improvement on myocardial ischemia of coronary heart disease. Meanwhile, the effect of Danshen extract group was better than Sanqi power group.

R285.5

廣東省重點(diǎn)領(lǐng)域研發(fā)計(jì)劃項(xiàng)目（2020B1111110002）；國(guó)家中醫(yī)藥管理局中藥標(biāo)準(zhǔn)化項(xiàng)目（ZYBZH-C-GD-05）；天津市科技計(jì)劃項(xiàng)目（15ZXXYSY00070）